The trading price of GSK Plc ADR (NYSE:GSK) floating higher at last check on current market day and closing at $40.94, 0.18% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $40.71 and $41.105. The company’s P/E ratio in the trailing 12-month period was 21.25, while its 5Y monthly beta was 0.274. In examining the 52-week price action we see that the stock hit a 52-week high of $44.67 and a 52-week low of $31.72. Over the past month, the stock has gained 8.96% in value.
GSK Plc ADR, whose market valuation is $83.00 billion at the time of this writing, is expected to release its quarterly earnings report on 2025-Apr-29. The dividend yield on the company stock is 3.92%, while its Forward Dividend ratio is 1.61. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 1.16 per share this quarter, however they have predicted annual earnings per share of 4.36 for current year and 4.86 for next year.
Analysts have forecast the company to bring in revenue of 7.92B for the current quarter, with the likely lows of 7.72B and highs of 8.29B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 32.24B.
On the technical side, indicators suggest GSK has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned GSK a recommendation rating is 8. Out of them, 4 rate it a Hold, while 4 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged GSK Plc ADR (GSK) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 2.18, which symbolizes a positive outlook. A quick review shows that GSK’s price is currently 1.64% off the SMA20 and 7.28% off the SMA50. The RSI metric on the 14-day chart is currently showing 56.81, and weekly volatility stands at 2.67%. When measured over the past 30 days, the indicator reaches 1.62%. GSK Plc ADR (NYSE:GSK)’s beta value is currently sitting at 0.52, while the Average True Range indicator is currently displaying 0.79. With analysts defining $35.25-$35.25 as the low and high price targets, we arrive at a consensus price target of $35.25 for the trailing 12-month period. The current price is about 13.9% off the estimated low and 13.9% off the forecast high, based on this estimate. Investors will be thrilled if GSK’s share price rises to $35.25, which is the median consensus price. At that level, GSK’s share price would be 13.9% above current price.
To see how GSK Plc ADR stock has been performing today in comparison to its peers in the industry, here are the numbers: GSK stock’s performance was 0.18% at last check in today’s session, and -0.43% in the past year. GSK Plc ADR has a P/E ratio of 21.25.
An evaluation of the daily trading volume of GSK Plc ADR (NYSE:GSK) indicates that the 3-month average is 5.33 million. However, this figure has increased over the past 10 days to an average of 4.49.
Currently, records show that 2.04 billion of the company’s shares remain outstanding. The insiders hold 0.00% of outstanding shares, whereas institutions hold 18.11%. The stats also highlight that short interest as of 2025-05-30, stood at 16.67 million shares, resulting in a short ratio of 3.18 at that time. From this, we can conclude that short interest is 82.00 of the company’s total outstanding shares. It is noteworthy that short shares in May were down slightly from the previous month’s figure, which was 17.37 million. However, since the stock’s price has seen 21.04% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
